CO6260102A2 - Cepas de mycoplasma gallisepticum atenuadas - Google Patents

Cepas de mycoplasma gallisepticum atenuadas

Info

Publication number
CO6260102A2
CO6260102A2 CO10030400A CO10030400A CO6260102A2 CO 6260102 A2 CO6260102 A2 CO 6260102A2 CO 10030400 A CO10030400 A CO 10030400A CO 10030400 A CO10030400 A CO 10030400A CO 6260102 A2 CO6260102 A2 CO 6260102A2
Authority
CO
Colombia
Prior art keywords
gallisepticum
bacterium
protein
live attenuated
bacteria
Prior art date
Application number
CO10030400A
Other languages
English (en)
Inventor
Mahesh Kumar
Muhammad Ayub Khan
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CO6260102A2 publication Critical patent/CO6260102A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona bacterias Mycoplasma gallisepticum vivas atenuadas que exhiben una expresión reducida de una proteína identificada como MGA_0621. En ciertas realizaciones, las bacterias atenuadas pueden exhibir adicionalmente una expresión reducida de una o más proteínas seleccionadas del grupo constituido por piruvato deshidrogenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteína ribosómica L35 respecto a una bacteria M. gallisepticum de tipo silvestre. Se proporcionan también vacunas y procedimientos de vacunación que implican el uso de las bacterias M. galIisepticum viva atenuadas y procedimientos para preparar bacterias M. gallisepticum vivas atenuadas. Se proporciona una cepa de M. gallisepticum viva atenuada ejemplar, designada MGx+47, que se mostró por análisis proteómico que exhibía una expresión significativamente reducida de MGA_0621, y que se mostró que era segura y eficaz cuando se administraba como vacuna contra infección por M. gallisepticum en pollos. 1.- Una bacteria Mycoplasma gallisepticum viva atenuada que exhibe una expresión reducida de una proteína que tiene la secuencia aminoacídica de SEQ ID NO: 1 respecto a una Mycoplasma gallisepticum de tipo silvestre. 2.- La bacteria de la Reivindicación 1, en la que dicha bacteria exhibe al menos un 25% menos de expresión de dicha proteína respecto a una Mycoplasma gallisepticum de tipo silvestre. 3.- La bacteria de la Reivindicación 2, en la que dicha bacteria exhibe al menos un 50% menos de expresión de dicha proteína respecto a una Mycoplasma gallisepticum de tipo silvestre.
CO10030400A 2007-09-11 2010-03-15 Cepas de mycoplasma gallisepticum atenuadas CO6260102A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99344707P 2007-09-11 2007-09-11

Publications (1)

Publication Number Publication Date
CO6260102A2 true CO6260102A2 (es) 2011-03-22

Family

ID=40024216

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10030400A CO6260102A2 (es) 2007-09-11 2010-03-15 Cepas de mycoplasma gallisepticum atenuadas

Country Status (22)

Country Link
US (4) US7935356B2 (es)
EP (2) EP2564868A1 (es)
JP (2) JP5451619B2 (es)
KR (2) KR20120014041A (es)
CN (1) CN101896195B (es)
AR (1) AR068418A1 (es)
AU (1) AU2008299913B2 (es)
BR (1) BRPI0817334A8 (es)
CA (1) CA2699410C (es)
CL (1) CL2008002675A1 (es)
CO (1) CO6260102A2 (es)
ES (1) ES2437593T3 (es)
HK (1) HK1145627A1 (es)
ME (1) ME00982B (es)
MX (1) MX2010002866A (es)
NZ (1) NZ583829A (es)
PL (1) PL2200640T3 (es)
RU (1) RU2441909C2 (es)
TW (1) TW200918666A (es)
UA (1) UA98506C2 (es)
WO (1) WO2009035644A1 (es)
ZA (1) ZA201001740B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
EP2571980A4 (en) * 2010-05-19 2014-02-26 Bioproperties Pty Ltd METHOD RELATED TO A WEAKEN MYCOPLASMA
CN102168073B (zh) * 2010-11-30 2013-03-20 瑞普（保定）生物药业有限公司 一种提高疫苗生产中鸡毒支原体增殖能力的方法
CN103074246B (zh) * 2012-08-31 2015-09-02 南京天邦生物科技有限公司 一种低血清高效培养鸡毒支原体弱毒株培养基及其制备方法
CN107446859B (zh) * 2017-09-02 2020-12-18 河南省农业科学院畜牧兽医研究所 一株鸡毒支原体及其应用
CN112159479B (zh) * 2020-10-15 2022-03-22 福建农林大学 一种鸡毒支原体多抗原表位融合蛋白pMG-mEA及其应用
CN114045298B (zh) * 2021-09-09 2023-10-20 武汉科前生物股份有限公司 一种鸡滑液囊支原体亚单位疫苗及制备方法及应用
CN114940955B (zh) * 2022-05-10 2023-08-11 兆丰华生物科技(南京)有限公司 一种鸡毒支原体弱毒疫苗株及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566833B1 (fr) * 1984-06-27 1986-11-14 Inst Francais Du Petrole Methode et perfectionnement aux outils de forage comportant des passages d'eau permettant une grande efficacite du nettoyage du front de taille
ES2058237T3 (es) * 1987-09-18 1994-11-01 Akzo Nv Metodo para la preparacion de una vacuna para combatir la infeccion mycoplasmica en aves de corral.
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US7599736B2 (en) * 2001-07-23 2009-10-06 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
EP1063297B1 (en) * 1999-06-22 2008-12-17 Korea Kumho Petrochemical Co. Ltd. Farnesyl pyrophosphate synthase (FPS) derived from seedlings of sunflower (Helianthus annus)
JP4723707B2 (ja) * 1999-12-22 2011-07-13 パナソニック電工株式会社 痩身器具
US6885888B2 (en) * 2000-01-20 2005-04-26 The Cleveland Clinic Foundation Electrical stimulation of the sympathetic nerve chain
US6922590B1 (en) * 2000-11-21 2005-07-26 Advanced Bionics Corporation Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US20020187162A1 (en) * 2001-04-21 2002-12-12 Geary Steven J. Use of a live attenuated Mycoplasma gallisepticum strain as a vaccine and vector for the protection of chickens and turkeys from respiratory disease
US6721603B2 (en) * 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US7239912B2 (en) * 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US7551964B2 (en) * 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7076292B2 (en) * 2002-04-25 2006-07-11 Medtronic, Inc. Optical communication of neurostimulation-system information
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
US7155278B2 (en) * 2003-04-21 2006-12-26 Medtronic, Inc. Neurostimulation to treat effects of sleep apnea
RU2420570C2 (ru) * 2003-07-25 2011-06-10 Бёрингер Ингельхайм Ветмедика, Инк. Lawsonia intracellularis ЕВРОПЕЙСКОГО ПРОИСХОЖДЕНИЯ И ВАКЦИНЫ, ДИАГНОСТИЧЕСКИЕ АГЕНТЫ НА ЕЕ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains

Also Published As

Publication number Publication date
AU2008299913B2 (en) 2014-05-08
EP2200640B1 (en) 2013-10-23
AU2008299913A1 (en) 2009-03-19
US7935356B2 (en) 2011-05-03
WO2009035644A1 (en) 2009-03-19
CN101896195B (zh) 2013-04-03
MX2010002866A (es) 2010-04-01
RU2010108641A (ru) 2011-10-20
ME00982B (me) 2011-04-30
HK1145627A1 (en) 2011-04-29
CA2699410A1 (en) 2009-03-19
US20130302373A1 (en) 2013-11-14
CL2008002675A1 (es) 2008-11-07
US20130022547A1 (en) 2013-01-24
BRPI0817334A8 (pt) 2016-03-29
UA98506C2 (en) 2012-05-25
KR101176717B1 (ko) 2012-09-03
PL2200640T3 (pl) 2014-02-28
JP2010538646A (ja) 2010-12-16
EP2200640A1 (en) 2010-06-30
US20090068232A1 (en) 2009-03-12
CA2699410C (en) 2013-08-20
ZA201001740B (en) 2014-03-26
CN101896195A (zh) 2010-11-24
NZ583829A (en) 2011-12-22
AR068418A1 (es) 2009-11-18
KR20100061526A (ko) 2010-06-07
US8298552B2 (en) 2012-10-30
RU2441909C2 (ru) 2012-02-10
BRPI0817334A2 (pt) 2015-03-24
EP2564868A1 (en) 2013-03-06
JP2014027950A (ja) 2014-02-13
JP5451619B2 (ja) 2014-03-26
ES2437593T3 (es) 2014-01-13
US20110189099A1 (en) 2011-08-04
TW200918666A (en) 2009-05-01
KR20120014041A (ko) 2012-02-15

Similar Documents

Publication Publication Date Title
CO6260102A2 (es) Cepas de mycoplasma gallisepticum atenuadas
MX2018014573A (es) Vacuna contra el virus del zika.
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
PE20141482A1 (es) Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
CO6460761A2 (es) Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento
RS54687B1 (en) COMPOSITION OF MYCOBACTERIAL ANTIGENS
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
CL2008003202A1 (es) Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
AR065076A1 (es) Vacuna contra el papilomavirus
BRPI0409789B8 (pt) célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva
CL2008003845A1 (es) Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina.
CL2023001816A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
AR088176A1 (es) Secuencias de aminoacidos para el control de patogenos
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
RU2009139262A (ru) Улучшенные вакцины против bordetella pertussis на основе мутантных гликозилтрансфераз lps
AR085800A1 (es) Vacuna de rinitis equina
AR048429A1 (es) Aislados antigenicos y vacunas del virus de la bursitis infecciosa
MX2023007376A (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada.
Kogut et al. Electron-beam irradiation inactivation of salmonella: effects on innate immunity and induction of protection against Salmonella enterica serovar Typhimurium challenge of chickens
RU2017105223A (ru) Аттенуированный штамм вируса репродуктивно-респираторного синдрома свиней (ррсс) и его возможное применение в средствах для иммунизации
CO6160333A2 (es) Bacterinas tratadas con calor y vacunas de emulsion preparadas a partir de estas bacterinas tratadas con calor
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
BR112016006468A2 (pt) processo e composição de tratamento de um material vegetal

Legal Events

Date Code Title Description
FG Application granted